Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bexotegrast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bexotegrast (PLN-74809) is under development for the treatment of primary sclerosing cholangitis, idiopathic pulmonary fibrosis (IPF), liver fibrosis and COVID-19-related acute respiratory distress syndrome. The drug candidate acts by targeting integrin alpha 5 beta 6 and integrin alpha 5 beta 1.
Pliant Therapeutics overview
Pliant Therapeutics is a Pharmaceutical company. It discovers and develops therapeutics to treat fibrotic diseases. It is investigating PLN-74809, an oral, small molecule, dual-selective inhibitor targeting idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of late stage liver fibrosis associated with nonalcoholic steatohepatitis (NASH). The company is also evaluating therapies to treat muscular dystrophies, solid tumors, and cancer. It works in partnership with Novartis AG and other institutions, universities, medical centers, physicians and researchers to develop its products. Pliant Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of Bexotegrast’s drug-specific PTSR and LoA scores, buy the report here.